➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Harvard Business School
Colorcon
Mallinckrodt
Dow

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DORZOLAMIDE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for dorzolamide hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00108017 ↗ Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2005-04-01 This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00140049 ↗ A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma Completed Pfizer Phase 4 2005-07-01 To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon & 4 PM during a 12 week treatment.
NCT00152932 ↗ Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide Unknown status Merck Frosst Canada Ltd. N/A 2005-05-01 Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic nerve perfusion. The objectives of this study are to learn the effects of dorzolamide on the retinal and optic nerve blood flow of glaucoma patients. The present study is a prospective, randomized, double-masked, crossover design study of newly diagnosed or already treated patients with early glaucoma. The investigators will check ocular blood flow parameters using the Canon Laser Blood Flowmeter (CLBF), used to evaluate retinal arteriole blood flow, and the Heidelberg retinal flowmeter (HRF), which measures blood flow through capillary beds in the retina and optic nerve head. Any demonstrated improvements to retinal and optic nerve blood flow with dorzolamide, will mean that the drug may protect against ischaemic nerve and retinal damage. Any documented improvement in flow could lead to a major change in the management of glaucoma patients as well as other retinal ischemic diseases such as diabetic retinopathy and central retinal vein occlusion.
NCT00152932 ↗ Ocular Blood Flow in Early Glaucoma Patients Before and After Treatment With Dorzolamide Unknown status University Health Network, Toronto N/A 2005-05-01 Impaired ocular blood flow is an important risk factor in the pathogenesis of primary open angle glaucoma (POAG). A few studies suggest that topical dorzolamide 2% may increase optic nerve perfusion. The objectives of this study are to learn the effects of dorzolamide on the retinal and optic nerve blood flow of glaucoma patients. The present study is a prospective, randomized, double-masked, crossover design study of newly diagnosed or already treated patients with early glaucoma. The investigators will check ocular blood flow parameters using the Canon Laser Blood Flowmeter (CLBF), used to evaluate retinal arteriole blood flow, and the Heidelberg retinal flowmeter (HRF), which measures blood flow through capillary beds in the retina and optic nerve head. Any demonstrated improvements to retinal and optic nerve blood flow with dorzolamide, will mean that the drug may protect against ischaemic nerve and retinal damage. Any documented improvement in flow could lead to a major change in the management of glaucoma patients as well as other retinal ischemic diseases such as diabetic retinopathy and central retinal vein occlusion.
NCT00273429 ↗ Cosopt Versus Xalatan Completed Pharmaceutical Research Network Phase 4 2005-04-01 To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dorzolamide hydrochloride

Condition Name

Condition Name for dorzolamide hydrochloride
Intervention Trials
Glaucoma 22
Ocular Hypertension 22
Open-Angle Glaucoma 9
Primary Open Angle Glaucoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for dorzolamide hydrochloride
Intervention Trials
Glaucoma 37
Ocular Hypertension 23
Glaucoma, Open-Angle 21
Hypertension 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for dorzolamide hydrochloride

Trials by Country

Trials by Country for dorzolamide hydrochloride
Location Trials
United States 30
Greece 5
Italy 4
Canada 3
Mexico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for dorzolamide hydrochloride
Location Trials
Pennsylvania 5
Illinois 4
Florida 3
Texas 3
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for dorzolamide hydrochloride

Clinical Trial Phase

Clinical Trial Phase for dorzolamide hydrochloride
Clinical Trial Phase Trials
Phase 4 22
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for dorzolamide hydrochloride
Clinical Trial Phase Trials
Completed 34
Unknown status 7
Recruiting 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for dorzolamide hydrochloride

Sponsor Name

Sponsor Name for dorzolamide hydrochloride
Sponsor Trials
Merck Sharp & Dohme Corp. 6
Laboratorios Sophia S.A de C.V. 4
Allergan 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for dorzolamide hydrochloride
Sponsor Trials
Other 39
Industry 26
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Moodys
Johnson and Johnson
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.